Associate Professor of Demography,
Harvard T.H. Chan School
As of 4th March 2016
– 5900 suspected cases
– 640 confirmed for microcephaly
– Only 80 had zika virus Note: Zika (or dengue) found in 80 out of 640 (12.5%) cases of confirmed microcephaly. 87.5% of microcephaly cases tested negative for zika (or dengue) virus. Dengue virus may be creating false positives for zika. Zika and dengue are very similar.
Unknown to most Americans is that dengue fever has been the intense focus of US Army and CIA biological warfare researchers for over 50 years. Ed Regis notes in his excellent history of Fort Detrick, “The Biology of Doom,” that as early as 1942 leading biochemists at the installation placed dengue fever on a long list for serious consideration as a possible weapon. In the early 1950s, Fort Detrick, in partnership with the CIA, launched a multi-million dollar research program under which dengue fever and several addition exotic diseases were studied for use in offensive biological warfare attacks. Assumably, because the virus is generally not lethal, program planners viewed it primarily as an incapacitant. Reads one CIA Project Artichoke document: “Not all viruses have to be lethal … the objective includes those that act as short-term and long-term incapacitants.”
“…The basic premise behind the flying mosquito vaccines is that an insect will be genetically modified to produce antibodies to a certain disease in their saliva, which is then transmitted to the individual when the mosquito bites them.
There is a host of problems with this method that range from the moral to the scientific. First, the presence of antibodies does not necessarily mean immunity, and the transfer of them does not in any way provide immunization to the subject being injected with them. The science related to antibodies and immunity is still largely unsettled. Vaccines, themselves, are completely ineffective and have never been proven effective by a study that was not connected to a drug company or a pharmaceutical company. They are, essentially, faith-based medicine…”
“The ability to create and modify ‘organic’ materials on increasingly larger scales has occurred with a number of breakthroughs in genetic engineering including automated DNA sequencing, DNA synthesis, the advent of computational bioinformatics, and the creation of genetically modified organisms. Today, Intrexon’s expertise in designing DNA and constructing complex gene programs utilizing a modular, scalable approach with an embedded capacity to predict the viability of a biological solution, places it at the leading-edge of this growing synthetic biology discipline.”
How the technology works from Oxitec Limited on Vimeo. Note: These posts on Oxitec and their GM Mosqitoes are not meant to induce fear or anxiety. My intention is that an awareness will actually diffuse any fear-mongering narrative that aims to profit and support the agenda of the gene splicers!
OX513A is a bisex RIDL strain. Males are released to mate with wild females. The progeny of such matings die as late larvae or pupae. Continual releases of sufficient numbers of RIDL males will reduce the target population to below the level needed to transmit disease. The late lethality means that RIDL larvae compete with wild-type larvae for resources,adding to the overall effectiveness of control. Before release, male and female pupae are separated mechanically, exploiting the fact that they are naturally significantly different in size. The strain contains the DsRed marker which is clearly visible in larvae, a useful tool for quality control in production and effective monitoring in the field. OX513A is available in Asian and Latin American genetic backgrounds.
Status OX513A has regulatory approvals for import and contained testing in Brazil, Cayman Islands, France, India, Malaysia, Singapore, Thailand, USA and Vietnam. Open field trials have taken place in both Grand Cayman and Malaysia, and are currently also underway in Brazil.
GoViral is studying how community viral diagnostic information and symptom information combined can be used to understand an individual’s risk of influenza. We would like you to provide you with an easy to use flu test you can use at home if you are sick.
GoViral Saliva Sample Instructions
GoViral Nasal Swab Instructions
Decentralised testing centres equipped with miniPCR kits and self/community collected samples from the sick. These serve as monitoring stations/hubs for existing diseases and future (expected) outbreaks.
The medical and government professionals seeking real benefit for their communities will be keen on this modest detection system
The technology, developed by MIT professor and Howard Hughes Medical Institute investigator Sangeeta Bhatia, relies on nanoparticles that interact with tumor proteins called proteases, each of which can trigger release of hundreds of biomarkers that are then easily detectable in a patient’s urine
This could be modified for various other applications such as Ebola, malaria, Lassa fever, Dengue and by the Kenyan Health authority to detect contaminants like b-HCG in the Tetanus vaccines or other vaccines.
The research branch of the U.S. Department of Defense wants to know when and where the next outbreak of the mosquito-borne chikungunya virus will occur, and it’s offering $150,000 for the best new approach. The Defense Advanced Research Projects Agency (DARPA) today announced its first health-related challenge, which asks scientific teams to forecast over 6 months how the debilitating disease might spread in the Americas and the Caribbean
Hepburn says DARPA wants to find technologies that U.S. health officials can use to make decisions in the case of an outbreak. “It’s one thing to know what’s happening on the ground currently,” he says, “but really to design your response decisions, you need to know what’s going to happen next.” Forecasts of how severe an outbreak will be, where it might move, and who is most susceptible would help health officials concentrate resources in the right places, killing mosquitos and their larvae, or eliminating out potential breeding grounds in places of high risk.
The challenge drew inspiration from a similar competition at the U.S. Centers for Disease Control and Prevention (CDC) focused on influenza prediction—a field that has received more scientific attention than chikungunya and benefits from an annual influx of data during the peak season. CDC’s winning submission, announced in June, combined Google and CDC data to accurately predict the peak and intensity of the 2013 to 2014 season.